The Japanese pharmaceutical market, with sales of $60 billion in 2005, is the second largest market comprising approximately 11% of the global market. Despite the size of this market, many multinational companies struggle to synchronize or integrate
Drug development in Japan with the US/EU. As a result, there continues to be a significant lag in new drug approvals in Japan as compared to the West.

There are many barriers to successful drug development in Japan and this course has been specifically designed to provide some insight into this process. Through a series of highly interactive presentations and case studies, this course will explore the
Developmental requirements, regulatory environment, and commercial opportunities for medicines in Japan.